In response to the announcement of Trump administration proposals to allow importation of certain prescription drugs, the American Pharmacists Association (APhA) expressed its overwhelming concerns for patient safety. Read More »

Luye Pharma Group has announced submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for LY03005, a new chemical drug for the treatment of major depressive disorder. It is also the second U.S. FDA NDA submission in the central nervous system (CNS) filed by the company. Read More »